This article is more than 5 years old. Information may no longer be current.

Bausch & Lomb, CrystalGenomics enter research and development agreement

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCHESTER, N.Y. — Bausch & Lomb and CrystalGenomics have entered into a joint research and development agreement to investigate prospective new treatments for inflammatory ophthalmic diseases, according to a joint press release from the companies.

Under the agreement, CrystalGenomics will provide novel pharmaceutical candidate compounds, while Bausch & Lomb will develop product formulations, perform preclinical and clinical studies, and market all potential products, the release said.

Financial terms of the agreement have not been disclosed.